• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
University of Michigan Comprehensive Cancer Center - Product Pipeline Review - Q4 2010 Product Image

University of Michigan Comprehensive Cancer Center - Product Pipeline Review - Q4 2010

  • ID: 1447156
  • December 2010
  • Region: Michigan
  • 101 pages
  • Global Markets Direct

University of Michigan Comprehensive Cancer Center – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “University of Michigan Comprehensive Cancer Center – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by University of Michigan Comprehensive Cancer Center.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage READ MORE >



List of Tables
List of Figures
University of Michigan Comprehensive Cancer Center Snapshot
University of Michigan Comprehensive Cancer Center Overview
Key Information
Key Facts
University of Michigan Comprehensive Cancer Center – Research and Development Overview
Key Therapeutic Areas
University of Michigan Comprehensive Cancer Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
University of Michigan Comprehensive Cancer Center – Pipeline Products Glance
University of Michigan Comprehensive Cancer Center – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
University of Michigan Comprehensive Cancer Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
University of Michigan Comprehensive Cancer Center – Drug Profiles
Enbrel
Product Description
Mechanism of Action
R&D Progress
Interleukin-2
Product Description
Mechanism of Action
R&D Progress
AG-013736
Product Description
Mechanism of Action
R&D Progress
Anastrozole
Product Description
Mechanism of Action
R&D Progress
Bexxar
Product Description
Mechanism of Action
R&D Progress
Calcitriol + Cisplatin + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Carfilzomib + Revlimid + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Celecoxib + Capecitabine + Irinotecan
Product Description
Mechanism of Action
R&D Progress
Cetuximab
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Chemoradiation + Tetrathiomolybdate
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Cetuximab + 5-Fluorouracil + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Clofarabine + Busulfan + Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + sirolimus
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Trastuzumab
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Xeloda
Product Description
Mechanism of Action
R&D Progress
eflornithine
Product Description
Mechanism of Action
R&D Progress
Fenretinide
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Busulfan + Allogeneic Hematopoietic Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Busulfan + Radiation Therapy + Allogeneic Stem Cell Transplantion
Product Description
Mechanism of Action
R&D Progress
Fludarabine phosphate + Busulfan + Tacrolimus + Mycophenolate mofetil + Vorinostat + Allogeneic hematopoietic stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin + Celecoxib
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Intensity Modulated Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Oxaliplatin + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Gleevec
Product Description
Mechanism of Action
R&D Progress
Herceptin for Breast Cancer (University of Michigan Cancer Center)
Product Description
Mechanism of Action
R&D Progress
Ifosfamide + Doxorubicin
Product Description
Mechanism of Action
R&D Progress
Interleukin-2 + Tumor-Pulsed Dendritic Cell Vaccine
Product Description
Mechanism of Action
R&D Progress
Irinotecan + 5-Fluorouracil + Leucovorin + Tetrathiomolybdate
Product Description
Mechanism of Action
R&D Progress
Lapatinib_
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Bortezomib + Dexamethasone + Doxil
Product Description
Mechanism of Action
R&D Progress
Mitomycin C + Cetuximab + Irinotecan
Product Description
Mechanism of Action
R&D Progress
oxaliplatin + gemcitabine
Product Description
Mechanism of Action
R&D Progress
Palonosetron
Product Description
Mechanism of Action
R&D Progress
Palonosetron_
Product Description
Mechanism of Action
R&D Progress
Paraplatin + Taxol
Product Description
Mechanism of Action
R&D Progress
PEG-IFN-a2a
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Revlimid + Velcade + Dexamethasone + Doxil
Product Description
Mechanism of Action
R&D Progress
sunitinib
Product Description
Mechanism of Action
R&D Progress
Tacrolimus + Mycophenolate + Etanercept + Methoxsalen + Stem cell transplant
Product Description
Mechanism of Action
R&D Progress
Taxotere
Product Description
Mechanism of Action
R&D Progress
Tetrathiomolybdate (TM)
Product Description
Mechanism of Action
R&D Progress
trastuzumab
Product Description
Mechanism of Action
R&D Progress
Trastuzumab + Paclitaxel + Carboplatin + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Tumor Lysate Pulsed Dendritic Cell Vaccine + Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Velcade + Doxil + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
vorinostat
Product Description
Mechanism of Action
R&D Progress
Alemtuzumab
Product Description
Mechanism of Action
R&D Progress
Iodine I 131 Tositumomab
Product Description
Mechanism of Action
R&D Progress
KLH-Pulsed Dendritic Cell + Tumoral Irradiation
Product Description
Mechanism of Action
R&D Progress
resveratrol
Product Description
Mechanism of Action
R&D Progress
Velcade + Bexxar
Product Description
Mechanism of Action
R&D Progress
Vorinostat + Docetaxel
Product Description
Mechanism of Action
R&D Progress
University of Michigan Comprehensive Cancer Center – Pipeline Analysis
University of Michigan Comprehensive Cancer Center – Pipeline Products by Therapeutic Class
University of Michigan Comprehensive Cancer Center Pipeline Products By Target
University of Michigan Comprehensive Cancer Center – Pipeline Products by Route of Administration
University of Michigan Comprehensive Cancer Center – Pipeline Products by Molecule Type
University of Michigan Comprehensive Cancer Center – Recent Pipeline Updates
University of Michigan Comprehensive Cancer Center - Dormant Projects
University of Michigan Comprehensive Cancer Center – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS